Abstract:To identify host factors that influence SARS-coronavirus (SARS-CoV) replication, we performed an siRNA library screen targeting the human kinome. Protein kinases are key regulators of many cellular functions and the systematic knockdown of their expression should provide a broad perspective on factors and pathways promoting or antagonizing coronavirus replication. In addition to 40 proviral proteins that promote SARS-CoV replication, our study identified 90 factors with an antiviral effect. Pathway analysis grouped subsets of these factors in specific cellular pathways, like the innate immune response and the metabolism of complex lipids, which thus appear to play an important role in SARS-CoV-infected cells. Two factors were selected for more extensive validation and follow-up experiments. In cells depleted for the beta 2 subunit of the coatomer protein complex (COPB2), the strongest proviral hit, we observed reduced SARS-CoV protein expression and a 2-log reduction in virus yield. The effect of knockdown of the COPB2-related factors COPB1 and Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1) also suggested that COPI-coated vesicles and/or the early secretory pathway are important for SARS-CoV replication. Depletion of the antiviral double-stranded RNA-activated protein kinase (PKR) enhanced virus replication, and validation experiments using PKR-directed siRNAs confirmed increased SARS-CoV protein expression and virus production upon PKR depletion. The inventory of proand antiviral host factors and pathways described in this study expands our understanding of the replication of SARS-CoV, and may contribute to the identification of novel targets for antiviral therapy. Host factors in SARS-CoV replication 89 CH A PT ER 5 INTRODUCTION Positive-stranded RNA (+RNA) viruses interact with the infected host cell at many levels during their replicative cycle, and thus far numerous host cell proteins with a role in virus replication have been identified [60-65]. These include on the one hand host factors that are used by the virus during the various stages of its life cycle, and on the other hand factors that are part of the host defense against virus infection. Such proteins may constitute interesting targets in the development of novel antiviral strategies, as drug resistance is less likely to develop when cellular rather than viral functions are targeted. Antiviral drug resistance is a serious problem, in particular when combating RNA viruses, due to their high mutation rate and potential for rapid adaptation. Systems biology approaches have been instrumental in advancing our knowledge of individual proteins and cellular pathways that influence +RNA virus infection. For example, systematic functional genomics screens using small interfering RNA (siRNA) libraries have identified numerous host genes with a role in the replication of important human pathogens like West Nile virus [334], Dengue virus [335], human immunodeficiency virus 1 [336], hepatitis C virus [337-342], and influenza virus [338, 343, 344]. For coronaviruses a number of relevant host proteins were previously described ([321], and reviewed in [65, 320]), but the use of larger-scale siRNA screens to systematically identify such factors was not documented thus far. Coronaviruses, and other members of the order Nidovirales [286], have the largest RNA genomes known to date (27-31 kb [37]) and the complexity of their molecular biology clearly distinguishes them from other +RNA virus groups. Although infection with most human coronaviruses is associated with relatively mild respiratory disease [19, 345], the 2003 outbreak of severe acute respiratory syndrome (SARS) highlighted the potential of coronaviruses to cause lethal disease in humans. The zoonotic transfer of SARS-coronavirus (SARS-CoV), which likely originated from bats, initiated an outbreak that affected about 8,000 humans, with a mortality of about 10% [317]. Strikingly, a similar outbreak of coronavirus-induced severe respiratory disease has been developing in a number of Arab countries since April 2012, with 9 of the 15 confirmed cases thus far (March 2013) having a fatal outcome (http://www.who.int/csr/don/archive/disease/ coronavirus_infections/en/). The causative agent, human coronavirus EMC/2012, was recently identified as a previously unknown member of betacoronavirus subgroup 2c [15, 16]. Although the source of this emerging human pathogen remains to be identified, it is striking that – as in the case of SARS-CoV its closest known relatives are coronaviruses circulating in bats [16]. These recent developments highlight once again the relevance of the systematic dissection of coronavirus-host interactions and the development of antiviral approaches to combat coronavirus infection.

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses

Host Cell Targets for Unconventional Antivirals against RNA Viruses

Exploiting the Achilles’ Heel of Viral RNA Processing to Develop Novel Antivirals

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

Broad-spectrum antiviral inhibitors targeting pandemic potential RNA viruses

Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids

Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections

Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics

New perspective of small-molecule antiviral drugs development for RNA viruses

SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules

A kinome-wide siRNA screen identifies proviral and antiviral host factors in SARS-coronavirus replication, including PKR and early secretory pathway proteins

Novel and Potent Inhibitors Targeting DHODH Are Broad-Spectrum Antivirals Against RNA Viruses Including Newly-Emerged Coronavirus SARS-CoV-2.

Novel analogues of a nonnucleoside SARS-CoV-2 RdRp inhibitor as potential antivirotics

An Interferon-Beta Promoter Reporter Assay for High Throughput Identification of Compounds Against Multiple RNA Viruses

Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay

Discovery of C-Linked Nucleoside Analogues with Antiviral Activity against SARS-CoV-2

A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins

Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2

Discovery, Optimization and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.

Analysis of Viral RNA-host Protein Interactomes Enables Rapid Antiviral Drug Discovery